Authorship: In addition to Jain, Mass General Brigham authors include Nilesh P. Talele, Heena Kumra, Igor L. Gomes-Santos, William W. Ho, Patrick Andersson, Marie Siwicki, Peigen Huang, Dan G. Duda, Mikael J. Pittet and Dai Fukumura.
Paper cited: Talele NP, et al “IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity” Journal for ImmunoTherapy of Cancer 2025. DOI: 10.1136/jitc-2024-011404
Funding: This work was supported by Jain’s grants from NIH (R01CA269672, R01-CA259253, R01-CA208205, U01-CA261842, and U01-CA 224348, Outstanding Investigator Award R35-CA197743), the National Foundation for Cancer Research, Jane’s Trust Foundation, Niles Albright Research Foundation and Harvard Ludwig Cancer Center; Pittet’s grants from ISREC Foundation and NIH (P01-CA240239); Fukumura’s grants from NIH (R01-CA208205, R0-NS100808, R01-NS118929, and R01-MH110438), Duda’s grants from NIH (R01CA260872, R01CA254351, and R01CA24744). Telele’s Merck-CRI Irvington Fellowship and Kumra’s the Jane’s Trust Foundation Fellowship.
Disclosures: Jain received consultant fees from DynamiCure, SynDevRx; owns equity in Accurius, Enlight, SynDevRx; and served on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund; and received a grant from Sanofi. Duda received research grants from Exelixis, BMS, Bayer, and Surface Oncology. Pittet has served as a consultant for Acthera, ImmuneOncia, LegoChemBio, MaxiVax, Molecular Partners, Merck, Third Rock Ventures, UNIKUM, and Tidal. No funding or reagents from these companies were used in this study. The other authors have no competing interests to declare.
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.